| Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. | |
| | |
MedLine Citation:
|
PMID: 18499536 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N=10) was 5.8 percentage points (p<0.0001), average weight percentile (N=13) increased 8.6 points (p<0.001), BMI percentile (N=11) improved on average 1.22 points (p<0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p<0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies. |
| | |
Authors:
|
Alfredo Visca; Clark T Bishop; Sterling C Hilton; Valerie M Hudson |
Related Documents
:
|
6351266 - Ingested foreign material in mentally disturbed patients. 7457696 - Revision of gastric bypass. 1411956 - Laparoscopy: the preferred method of cholecystectomy in the morbidly obese. 2703296 - The dynamics of weight loss after gastric partition for gross obesity. 16473786 - Neonatal isolated critical aortic valve stenosis: balloon valvuloplasty or surgical val... 3595376 - Influence of alcohol on morbidity after colonic surgery. |
Publication Detail:
|
Type: Journal Article; Multicenter Study Date: 2008-05-21 |
Journal Detail:
|
Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Volume: 7 ISSN: 1569-1993 ISO Abbreviation: J. Cyst. Fibros. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-09-15 Completed Date: 2009-01-27 Revised Date: 2009-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 101128966 Medline TA: J Cyst Fibros Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 433-6 Citation Subset: IM |
Affiliation:
|
Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section. alfredo.visca@fastwebnet.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Biological Markers / analysis Body Weight Child Child, Preschool Cystic Fibrosis / drug therapy*, microbiology, physiopathology Female Glutathione / administration & dosage* Humans Infant Italy Male Observation Respiratory Function Tests Treatment Outcome United States Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 70-18-8/Glutathione |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Poly(amidosulfonic acid) modified glassy carbon electrode for determination of isoniazid in pharmace...
Next Document: Bench study of auto-CPAP devices using a collapsible upper airway model with upstream resistance.